Nonhuman Primate Reagent Resource

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3U24AI126683-05S1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $353,732
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    DIOGO MAGNANI
  • Research Location

    United States of America
  • Lead Research Institution

    University of Massachusetts Chan Medical School
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Disease models

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

U24 AI126683 - Parent Award AbstractNonhuman primates (NHPs) serve a crucial role in translational research as animal models for exploring thepathogenesis of infectious and noninfectious diseases, and for testing of biologic therapies and vaccines. Whilemany human diagnostic immunologic reagents cross react with the primate species commonly employed intranslational research, gaps exist for a substantial number of reagent targets. Furthermore, antibodies thattarget specific immune functions or deplete specific lymphocyte subpopulations in vivo have proven valuable indefining disease mechanisms or can be used as proof-of-concept for new therapies.For the past 15 years, the NIH Nonhuman Primate Reagent Resource has responded to needs of the scientificcommunity by developing, manufacturing and distributing NHP-specific reagents for in vitro diagnostics and forin vivo use. Utilization of this resource has grown dramatically since this program's inception. During the lastbudget year, we fulfilled 500 reagent requests from 126 investigators and distributed over 300 grams ofrecombinant antibody for administration to NHPs.Taking advantage of scientific advances and technological improvements in antibody development, engineering,expression and vectoring, we will continue to support the scientific community utilizing NHP models across allscientific disciplines.